Results 121 to 130 of about 1,126 (138)

Low immunogenicity of emicizumab in persons with haemophilia A

Haemophilia, 2021
Christophe Schmitt, Tiffany Chang, Sammy Chebon   +2 more
exaly  

Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring

Haemophilia, 2021
Tami Livnat, Ivan Budnik, Assaf A Barg
exaly  

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Haemophilia, 2022
Christine L Kempton, Joanne I Adamkewicz, Giancarlo Castaman   +2 more
exaly  

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

Haemophilia, 2020
Craig D Seaman
exaly  

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data

Haemophilia, 2021
Tami Livnat, Ivan Budnik, Assaf A Barg
exaly  

Emicizumab

2018
Tiede, Andreas, Wörmann, Bernhard, Klamroth, Robert, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +4 more
openaire   +1 more source

Emicizumab treatment and monitoring in a paediatric cohort: real-world data

British Journal of Haematology, 2020
Ilia Tamarin, Tami Livnat, Ivan Budnik
exaly  

Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab

Arteriosclerosis, Thrombosis, and Vascular Biology, 2020
Keiji Nogami, Koji Yada
exaly  

Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada

Haemophilia, 2023
Alfonso Iorio, Andrea N Edginton, Arun Keepanasseril   +2 more
exaly  

Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline

Haemophilia, 2020
Vince Jenkins, Anne Riddell, Will Lester
exaly